SBIR Phase I: Novel Biosensor for Monitoring of Theophylline using Personal Glucose Meter

这个小企业创新研究第一阶段项目旨在开发一种新技术，利用无处不在的个人血糖仪（PGMs）进行廉价和方便的药物茶碱家庭测试。茶碱被广泛用于治疗哮喘和慢性阻塞性肺疾病。该药有效范围窄，用药过量有不良副作用，建议经常检测血浆茶碱。该项目的技术是通过茶碱触发的酶促反应将血浆茶碱定量转化为葡萄糖，从而通过廉价、方便的pgm检测葡萄糖来监测茶碱。这项研究的更广泛的商业影响是治疗药物监测更方便和更低的成本。在个体化医疗时代，药物的剂量和药物本身一样重要。许多其他药物与茶碱类似，有效范围窄，过量服用后会产生不良副作用。目前，检测这类药物的水平需要去医院抽血，这既不方便、耗时又昂贵。这里提出的创新也可以转化为更简单、快速和廉价地测量其他药物的浓度。这里提出的创新可以用于一般的药物监测，这将对全球医疗保健的质量和负担能力产生重大影响。

This Small Business Innovation Research Phase I project aims to develop a new technology to utilize ubiquitous personal glucose meters (PGMs) for inexpensive and convenient at-home tests of the drug theophylline. Theophylline has been widely used to treat asthma and chronic obstructive pulmonary diseases. It has a narrow effective range and adverse side effects when overdosed, thus frequent test of plasma theophylline are recommended for patients using this drug. The technology in this project converts plasma theophylline into glucose quantitatively by a theophylline-triggered enzymatic reaction, so theophylline is monitored through glucose detection by inexpensive and convenient PGMs.The broader commercial impacts of this research are more convenience and lower costs for therapeutic drug monitoring. In the era of personalized medicine, the dosage of a drug is as important as the drug itself. Many other drugs are similar to theophylline in terms of narrow effective ranges and adverse side effects when overdosed. Currently, testing levels for these types of drugs requires hospital visits and blood draws, which are inconvenient, time consuming and costly. The proposed innovation here can also be translated to measure other drugs' concentrations more simply, quickly and cheaply. The innovation proposed here can be used for drug monitoring in general which will have great impact on the quality and affordability of healthcare worldwide.